Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 1529
Journal of Infectious Diseases & Therapy received 1529 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Open J Gate
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Can herbal treatment be better than the leading drugs? A comparison of Gene-Eden-VIR/Novirin, acyclovir and valacyclovir in oral herpes
5th International Congress on Infectious Diseases
Hanan Polansky, Adrian Javaherian and Edan Itzkovitz
Center for the Biology of Chronic Disease, USA
ScientificTracks Abstracts: J Infect Dis Ther
Abstract
Background: Our previous papers showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR/Novirin reduced the number and duration of genital herpes outbreaks with no adverse effects. These studies also revealed that the herbal Gene-Eden-VIR/Novirin is mostly superior to acyclovir, valacyclovir, and famciclovir drugs in genital herpes. This study tested the effect of Gene-Eden-VIR/Novirin in oral herpes (also called cold sores and fever blisters). Methods: The framework of the study was a retrospective chart review. The study included 68 participants. The participants took 1-4 capsules per day over a period of 2-36 months. The study included two FDA recommended controls: baseline and a no-treatment. Results: Gene-Eden-VIR/Novirin was effective in 89.3% of participants. The treatment reduced the mean number of outbreaks per year from 6.0 and 3.6 in the control groups to 2.0 in the treatment group (P<0.0001 and P=0.07, respectively). GeneEden-VIR/Novirin reduced the mean duration of outbreaks from 9.8 and 5.8 days in the control groups to 3.2 days in the treatment group (P<0.0001 and P=0.02, respectively). There were no reports of adverse experiences. Gene-Eden-VIR/Novirin was compared to acyclovir and valacyclovir in six tests. In all tests, Gene-Eden-VIR/Novirin showed higher efficacy. GeneEden-VIR/Novirin also showed superior safety. Conclusions: This clinical study showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR/Novirin reduced the number and duration of outbreaks in oral herpes without any adverse effects. The study also showed that the herbal Gene-Eden-VIR/Novirin had better clinical effects than acyclovir and valacyclovir, the leading drugs in the category. Based on these results, we recommend using the herbal Gene-Eden-VIR/Novirin as preventive treatment for oral herpes, and specifically, as an alternative to the acyclovir and valacyclovir drugs.Biography
Hanan Polansky is the Director of the Center for the Biology of Chronic Disease (CBCD). He is also developer of Computer Intuition, a psycholinguistic-based datamining program that analyzes scientific text and assigns a rating to all ideas found in the text.
Email:hpolansky@cbcd.net
